Immunoadsorption with protein A in humoral rejection of kidney transplants.
The presence of alloantibodies may play a role in accelerated or acute humoral rejection. Different therapeutic strategies based on a removal of anti donor antibodies and prevention of their resynthesis have been used in the management of transplant rejection episodes. Immunoadsorption with staphylococcal protein A, a method to selectively remove immunoglobulin G, may represent a new treatment to reverse humoral rejection in kidney transplantation. From 1991 to January 1996, such a method was used in 23 patients in whom an acute humoral rejection developed over a mean period of 14.1 +/- 9.5 days after operation. Twenty-two patients had been transplanted from living donors and one from a cadaveric donor. The ages ranged from 23 to 58 years (mean, 34 +/- 10 years). All transplants were performed according to a negative direct crossmatch. Basic immunosuppression included cyclosporine, steroids, azathioprine, and antilymphocyte globulin or monoclonal antibodies (OKT3). Rejection was diagnosed on the basis of hematochemical tests, Doppler ultrasonography, and kidney biopsy. Only steroid and monoclonal and polyclonal antibody resistant rejections with > 165% positive direct crossmatches against the donor were treated with Protein A immunoabsorption. The procedure used is based on the treatment of 2-3 plasma volumes for the first 2 days and then every other day until a negative crossmatch is obtained, together with improvement in clinical status (mean treatments, 7.3 +/- 4.5 [range, 4-23]; mean duration of treatment, 12.3 +/- 10.2 days [range, 3-44]). From the start of treatment, azathioprine is replaced by cyclophosphamide at a dose of 1-2 mg/kg/day. During treatment, a remarkable fall in immunoglobulin G levels is achieved on the first day, whereas immunoglobulin M titers remain constant, with a slight decrease in serum albumin. Immediately after treatment, a negative crossmatch was found in 22 (95.6%) of 23 patients. In six patients (26%), graft function did not recover, and one patient (4.3%) died. Preliminary results show that immunoabsorption with staphylococcal protein A may be an effective support in the treatment of humoral acute rejection, particularly when it is performed as soon as an early diagnosis of humoral rejection is made. In fact, such treatment has a highly selective adsorption, allows treatment of large volumes of plasma, and can achieve a rapid decrease in the titer of circulating immunoglobulins.
Pretagostini
R
R
2nd Surgical Clinic, La Sapienza University of Rome, Italy.
Berloco
P
P
Poli
L
L
Cinti
P
P
Di Nicuolo
A
A
De Simone
P
P
Colonnello
M
M
Salerno
A
A
Alfani
D
D
Cortesini
R
R
D000208:Acute Disease; D000328:Adult; D000917:Antibody Formation; D003404:Creatinine / Q000097:blood; D006084:Graft Rejection / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000302:isolation & purification; D007163:Immunosorbent Techniques; D007518:Isoantibodies / Q000302:isolation & purification; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology* / Q000502:physiology; D008875:Middle Aged; D013205:Staphylococcal Protein A
D007074:Immunoglobulin G; D007518:Isoantibodies; D013205:Staphylococcal Protein A; D003404:Creatinine